SHANDONG XINHUA (00719) announced that it has recently obtained the Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration (NMPA). The oral solution is indicated for the treatment of osteoporosis in postmenopausal women to prevent hip and vertebral fractures (vertebral compression fractures), as well as to increase bone mass in men with osteoporosis. According to relevant statistics, alendronate sodium generated sales of RMB 720 million in 2024 across three major channels in China, including public hospitals, primary healthcare institutions, and retail pharmacies.